Manufacturing: Page 13
-
Courtesy of Eli Lilly
Lilly to invest $400M in Indianapolis manufacturing facilities
The drugmaker expects its investment to create 100 new, highly skilled jobs based in Indianapolis.
By Kristin Jensen • Nov. 20, 2019 -
Lonza CEO Funk to step down after 9 months on job
Funk is leaving for personal reasons, Lonza reported in a brief statement, and will be replaced on an interim basis by chairman Albert Baehny.
By Kristin Jensen • Nov. 14, 2019 -
Jacob Bell/BioPharma Dive
Mylan plant warned by FDA over valsartan manufacturing
Regulators said Mylan's ways of identifying, testing and handling raw materials at an Indian plant aren't enough to prevent contamination.
By Kristin Jensen • Nov. 14, 2019 -
Teva to restart production of cancer drug after shortages stressed treatment
Vincristine, a drug used to treat childhood cancers, has been in short supply since Teva stopped producing it and manufacturing woes hit Pfizer, the sole other supplier.
By Ned Pagliarulo • Nov. 14, 2019 -
What pharma manufacturing can learn from M&Ms
As pharmaceuticals companies look to shift from batch to continuous production, manufacturers may take a page from the food industry's playbook.
By Gary Wollenhaupt • Nov. 12, 2019 -
Sanofi cuts chemical, water use in switch to continuous manufacturing
While the pharma industry had been slow to adopt continuous manufacturing, Sanofi's new plant in Framingham, Massachusetts, is one example of the benefits possible.
By Matt Leonard • Nov. 12, 2019 -
Takeda opens vaccine plant as dengue shot shows promise
A site in Germany will produce Takeda's dengue vaccine, newly supported by data that appears to show the drug as effective in protecting against the virus.
By Kristin Jensen • Nov. 7, 2019 -
Lonza taps Cryoport to bolster cell and gene therapy delivery
The Swiss manufacturer inked a deal with the cold chain specialist, which works with sector leaders like Gilead, Novartis and Bluebird bio.
By Kristin Jensen • Nov. 7, 2019 -
7 questions about ethylene oxide as FDA panel convenes
Agency advisers met again Thursday, having already encouraged the FDA to incentivize lower industry reliance on the controversial chemical.
By David Lim • Updated Nov. 7, 2019 -
Merck again borrows Gardasil supplies from CDC
Tapping the CDC's stockpile will lower sales of the HPV vaccine by about $120 million in the fourth quarter, Merck said.
By Kristin Jensen • Oct. 31, 2019 -
Jacob Bell/BioPharma Dive
FDA blames market failures for drug shortages
High-profile shortages of drugs like EpiPen and the chemotherapy vincristine have brought attention to a chronic problem, one that's spurred in part by what the FDA termed a "broken marketplace."
By Kristin Jensen • Oct. 31, 2019 -
BD suspends sterilization plant after FDA warning on device shortages
Public health concerns tied to ethylene oxide, a chemical used on half of medical devices requiring sterilization, have jeopardized sterilization facilities and the products they process.
By Maria Rachal • Oct. 28, 2019 -
Bluebird gets European green light for gene therapy production
Although Bluebird won EU approval for Zynteglo in June, the biotech delayed launching the one-time treatment to finalize manufacturing specifications.
By Kristin Jensen • Oct. 24, 2019 -
GSK hands 2 of its less profitable vaccines to Bavarian Nordic
The deal, worth about $335 million upfront, will help GSK simplify its supply chain and allow it to reinvest in higher growth areas, according to the company.
By Jacob Bell • Oct. 21, 2019 -
FDA warns losartan manufacturer of violations at Indian plant
The agency faulted Torrent Pharmaceuticals' executive oversight in a warning letter issued after the company voluntarily recalled lots of the antihypertensive.
By Kristin Jensen • Oct. 17, 2019 -
Courtesy of Sanofi
Sanofi upgrades biotech manufacturing with new Massachusetts plant
The French pharma has spent about $320 million over the past five years on the facility, part of a broader effort to retool how it makes the drugs it sells.
By Andrew Dunn • Oct. 15, 2019 -
Lilly shuttering UK neuroscience research site
Most employees will be relocated to a new facility in the area, although Lilly expects to lay off as many as 80 workers.
By Jonathan Gardner • Oct. 15, 2019 -
Sponsored by MilliporeSigma
Product characterization: Reveal your molecule earlier, faster, and with accuracy
Partnering for product characterization can streamline drug development and create efficiencies in moving from concept to clinic.
Oct. 15, 2019 -
Sponsored by MilliporeSigma
Product characterization: Reveal your molecule earlier, faster, and with accuracy
Partnering for product characterization can streamline drug development and create efficiencies in moving from concept to clinic.
Oct. 15, 2019 -
Gene therapy biotechs caught in manufacturing crunch
Rising demand for contract manufacturing services could push companies to invest more in their own capabilities despite the high cost.
By Ned Pagliarulo • Updated Oct. 11, 2019 -
Premier joins forces with Amphastar on 7 drugs in short supply
The agreement is another example of how healthcare companies are searching for new ways to address drug shortages.
By Kristin Jensen • Oct. 10, 2019 -
Cellectis turns to Lonza to manufacture cancer cell therapies
Lonza's Netherlands facility will complement Cellectis' own sites in development, the French biopharma said.
By Kristin Jensen • Oct. 3, 2019 -
FDA calls generic Zantac carcinogen levels 'unacceptable,' but pushes back against lab claims
Regulators say the third-party lab isn't using a suitable method in tests showing even higher levels of NDMA, a probable human carcinogen.
By Kristin Jensen • Oct. 3, 2019 -
After fanfare, Civica Rx delivers its 1st drugs
A Utah hospital was the first recipient of a medication produced by the hospital coalition, which set out last year to provide generics typically in short supply.
By Samantha Liss • Oct. 2, 2019 -
CVS suspends Zantac sales, as recalls widen over carcinogen fears
Citing an "abundance of caution," CVS announced it would halt sales of the commonly used heartburn drug until further notice.
By Andrew Dunn • Sept. 30, 2019
Previous
